Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3019794 | Revista Española de Cardiología Suplementos | 2006 | 10 Pages |
Abstract
The antiplatelet drugs, aspirin and clopidogrel, must be given as early as possible before coronary intervention. Abciximab is the most studied glycoprotein IIb/IIIa inhibitor. Its use is associated with the occurrence of fewer adverse events and better coronary artery patency before intervention. The use of thrombolytic drugs in combination with angioplasty is a promising way of extending mechanical reperfusion within the infarct but more studies must be carried out before it can be recommended. Other drugs, such as low-molecular-weight heparins and bivalirudin, have been studied in non-ST-elevation acute coronary syndrome but not in interventions for acute myocardial infarction.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ramón López-Palop, Maria Pilar Carrillo Sáez,